Hirotaka Kazama

Statistics

Publications

Citations

H-Index

Active since

2019

Affiliations

National Cancer Center Hospital East(Current)

Gunma University

Sanofi (Japan)

Yamaguchi University

Hirotaka Kazama is an author at National Cancer Center Hospital East specializing in serious adverse drug reactions, clinical pharmacology, and chemotherapy.

ORCID

Publications per year

2019–2020

Publications

Safety and efficacy of cabazitaxel in 660 patients with metastatic castration-resistant prostate cancer in real-world settings: results of a Japanese post-marketing surveillance study

Kazuhiro Suzuki, Nobuaki Matsubara, Hirotaka Kazama et al. · Japanese Journal of Clinical Oncology · 2019 · 42 citations · Full text

Medicine, Oncology, Pharmacology +17

Cabazitaxel in patients aged ≥80 years with castration-resistant prostate cancer: Results of a post-marketing surveillance study in Japan

Nobuaki Matsubara, Kazuhiro Suzuki, Hirotaka Kazama et al. · Journal of Geriatric Oncology · 2020 · 27 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Real-world efficacy and safety of two doses of cabazitaxel (20 or 25 mg/m2) in patients with castration-resistant prostate cancer: results of a Japanese post-marketing surveillance study

Hideyasu Matsuyama, Nobuaki Matsubara, Hirotaka Kazama et al. · BMC Cancer · 2020 · 22 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

1–3 of 3